Effects of DHA Supplementation on Vascular Function, Telomerase Activity in PBMC, Expression of Inflammatory Cytokines, and PPARγ-LXRα-ABCA1 Pathway in Patients With Type 2 Diabetes Mellitus: Study Protocol for Randomized Controlled Clinical Trial
Docosahexaenoic acid (DHA), as an omega-3 fatty acid, in a natural ligand of peroxisome proliferator-activated receptors (PPARs). Regarding the combinative effects of Nutrigenomics and Nutrigenetics and due to the lack of in vivo studies conducted using natural ligands of PPARs, we aimed to evaluate the effects of DHA supplementation on vascular function, telomerase activity, and PPARγ-LXRα-ABCA1 pathway, in patients with type 2 diabetes mellitus (T2DM), based on the Pro12Ala polymorphism in PPARγ encoding gene. 72 T2DM patients (36 dominant and 36 recessive allele carriers), aged 30-70, with body mass index of 18.5 to 35 kg/m2, will be participated in this double blind randomized controlled trial. In each group, stratification will be performed based on sex and age and participants will be randomly assigned to receive 2.4 g/day DHA or placebo (paraffin) for 8 weeks. PPARγ genotyping will be carried out using PCR-RFLP method; Telomerase activity will be estimated by PCR-ELISA TRAP assay; mRNA expression levels of target genes will be assessed using real time PCR. Serum levels of ADMA, sCD163 and adiponectin, will be measured using ELISA commercial kits. The present study is designed in order to help T2DM patients to modify their health conditions based on their genetic backgrounds, and to recommend the proper food ingredients as the natural agonists for PPARs in order to prevent and treat metabolic abnormalities of the disease.
Fowler MJ. Diabetes: Magnitude and mechanisms. Clinical Diabetes. 2007;25(1):25-8.
Rathmann W, Giani G. Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030 Response to Wild et al. Diabetes Care. 2004;27(10):2568-9.
Kouroumichakis I, Papanas N, Zarogoulidis P, Liakopoulos V, Maltezos E, Mikhailidis D. Fibrates: Therapeutic potential for diabetic nephropathy? European journal of internal medicine. 2012.
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26(2):77-82.
Tenenbaum A, Fisman EZ. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovascular diabetology. 2004;3(1):10.
Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB. Carotid-Wall Intima–Media Thickness and Cardiovascular Events. New England Journal of Medicine. 2011;365(3):213-21.
Al-Nimer MS, Hussein, II. Increased mean carotid intima media thickness in type 2 diabetes mellitus patients with non-blood pressure component metabolic syndrome: A preliminary report. International journal of diabetes in developing countries. 2009;29(1):19-22.
Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman RA, Briggs M, Deeb S, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. The EMBO Journal. 1996;15(19):5336.
Chinetti-Gbaguidi G, Fruchart J-C, Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Current opinion in pharmacology. 2005;5(2):177-83.
Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, et al. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochemical and Biophysical Research Communications. 2000;267(1):345-9.
Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart J-C, Duriez P, et al. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103(2):207-12.
Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000;275(22):16638-42.
Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, et al. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16^ I^ N^ K^ 4^ a. Journal of Clinical Investigation. 2005;115(11):3228.
Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL, et al. The PPARα/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle–Dependent Telomerase Activation. Circulation research. 2008;103(10):1155-63.
Minamino T, Komuro I. The role of telomerase activation in the regulation of vascular smooth muscle cell proliferation. Drug News Perspect. 2003;16(4):211.
Fuster JJ, Andrés V. Telomere biology and cardiovascular disease. Circulation research. 2006;99(11):1167-80.
Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nature Reviews Genetics. 2005;6(8):611-22.
Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90(6):703-10.
Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL, Li YJ. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol. 2005;371(5):401-7.
Rentoukas E, Tsarouhas K, Kaplanis I, Korou E, Nikolaou M, Marathonitis G, et al. Connection between Telomerase Activity in PBMC and Markers of Inflammation and Endothelial Dysfunction in Patients with Metabolic Syndrome. PloS one. 2012;7(4):e35739.
Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. Journal of lipid research. 2004;45(12):2161-73.
Hagiwara H, Nishiyama Y, Katayama Y. Effects of eicosapentaenoic acid on asymmetric dimethylarginine in patients in the chronic phase of cerebral infarction: a preliminary study. J Stroke Cerebrovasc Dis. 2011;20(5):474-8.
Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH. Polymorphism of peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. European journal of pharmacology. 2011;671(1-3):1-6.
Tang L, Tong Y, Cao H, Xie S, Yang Q, Zhang F, et al. The MTMR9 rs2293855 polymorphism is associated with glucose tolerance, insulin secretion, insulin sensitivity and increased risk of prediabetes. Gene. 2014;546(2):150-5.
Alvandi E, Akrami SM, Chiani M, Hedayati M, Nayer BN, Tehrani MR, et al. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Thyroid : official journal of the American Thyroid Association. 2011;21(4):373-82.
Mariani E, Meneghetti A, Formentini I, Neri S, Cattini L, Ravaglia G, et al. Different rates of telomere shortening and telomerase activity reduction in CD8 T and CD16 NK lymphocytes with ageing. Experimental gerontology. 2003;38(6):653-9.
Kellick KA, Bottorff M, Toth PP. A clinician's guide to statin drug-drug interactions. J Clin Lipidol. 2014;8(3 Suppl):S30-46.
Lim S, Oh PC, Sakuma I, Koh KK. How to balance cardiorenometabolic benefits and risks of statins. Atherosclerosis. 2014;235(2):644-8.
Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Annals of internal medicine. 2012;156(8):560-9.
Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. The American journal of cardiology. 2004;93(7):848-53.
Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92(3):536-41.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.